Literature DB >> 31787498

Poor Outcomes Related to Anterior Extension of Large Hemispheric Infarction: Topographic Analysis of GAMES-RP Trial MRI Scans.

Seyedmehdi Payabvash1, Guido J Falcone2, Gordon K Sze1, Abhi Jain3, Lauren A Beslow4, Nils H Petersen2, Kevin N Sheth5, W Taylor Kimberly6.   

Abstract

BACKGROUND: We aimed to assess the correlation of lesion location and clinical outcome in patients with large hemispheric infarction (LHI).
METHODS: We analyzed admission MRI data from the GAMES-RP trial, which enrolled patients with anterior circulation infarct volumes of 82-300 cm3 within 10 hours of onset. Infarct lesions were segmented and co-registered onto MNI-152 brain space. Voxel-wise general linear models were applied to assess location-outcome correlations after correction for infarct volume as a co-variate.
RESULTS: We included 83 patients with known 3-month modified Rankin scale (mRS). In voxel-wise analysis, there was significant correlation between admission infarct lesions involving the anterior cerebral artery (ACA) territory and its middle cerebral artery (MCA) border zone with both higher 3-month mRS and post-stroke day 3 and 7 National Institutes of Health Stroke Scale (NIHSS) total score and arm/leg subscores. Higher NIHSS total scores from admission through poststroke day 2 correlated with left MCA infarcts. In multivariate analysis, ACA territory infarct volume (P = .001) and admission NIHSS (P = .005) were independent predictors of 3-month mRS. Moreover, in a subgroup of 36 patients with infarct lesions involving right MCA-ACA border zone, intravenous (IV) glibenclamide (BIIB093; glyburide) treatment was the only independent predictor of 3-month mRS in multivariate regression analysis (P = .016).
CONCLUSIONS: Anterior extension of LHI with involvement of ACA territory and ACA-MCA border zone is an independent predictor of poor functional outcome, likely due to impairment of arm/leg motor function. If confirmed in larger cohorts, infarct topology may potentially help triage LHI patients who may benefit from IV glibenclamide. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01794182.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  Ischemic stroke; glibenclamide; glyburide; infarct location; lesion topography; malignant infarction

Mesh:

Substances:

Year:  2019        PMID: 31787498      PMCID: PMC8820410          DOI: 10.1016/j.jstrokecerebrovasdis.2019.104488

Source DB:  PubMed          Journal:  J Stroke Cerebrovasc Dis        ISSN: 1052-3057            Impact factor:   2.677


  21 in total

1.  'Malignant' middle cerebral artery territory infarction: clinical course and prognostic signs.

Authors:  W Hacke; S Schwab; M Horn; M Spranger; M De Georgia; R von Kummer
Journal:  Arch Neurol       Date:  1996-04

2.  Topographic Assessment of Acute Ischemic Changes for Prognostication of Anterior Circulation Stroke.

Authors:  Seyedmehdi Payabvash; Siamak Noorbaloochi; Adnan I Qureshi
Journal:  J Neuroimaging       Date:  2016-09-04       Impact factor: 2.486

3.  Recommendations for the management of cerebral and cerebellar infarction with swelling: a statement for healthcare professionals from the American Heart Association/American Stroke Association.

Authors:  Eelco F M Wijdicks; Kevin N Sheth; Bob S Carter; David M Greer; Scott E Kasner; W Taylor Kimberly; Stefan Schwab; Eric E Smith; Rafael J Tamargo; Max Wintermark
Journal:  Stroke       Date:  2014-01-30       Impact factor: 7.914

4.  Long-Term Outcomes in Patients Aged ≤70 Years With Intravenous Glyburide From the Phase II GAMES-RP Study of Large Hemispheric Infarction: An Exploratory Analysis.

Authors:  Kevin N Sheth; Nils H Petersen; Ken Cheung; Jordan J Elm; Holly E Hinson; Bradley J Molyneaux; Lauren A Beslow; Gordon K Sze; J Marc Simard; W Taylor Kimberly
Journal:  Stroke       Date:  2018-05-22       Impact factor: 7.914

5.  Safety and efficacy of intravenous glyburide on brain swelling after large hemispheric infarction (GAMES-RP): a randomised, double-blind, placebo-controlled phase 2 trial.

Authors:  Kevin N Sheth; Jordan J Elm; Bradley J Molyneaux; Holly Hinson; Lauren A Beslow; Gordon K Sze; Ann-Christin Ostwaldt; Gregory J Del Zoppo; J Marc Simard; Sven Jacobson; W Taylor Kimberly
Journal:  Lancet Neurol       Date:  2016-08-23       Impact factor: 44.182

6.  Glyburide Advantage in Malignant Edema and Stroke (GAMES-RP) Trial: Rationale and Design.

Authors:  Kevin N Sheth; Jordan J Elm; Lauren A Beslow; Gordon K Sze; W Taylor Kimberly
Journal:  Neurocrit Care       Date:  2016-02       Impact factor: 3.210

7.  Multivariate Prognostic Model of Acute Stroke Combining Admission Infarct Location and Symptom Severity: A Proof-of-Concept Study.

Authors:  Seyedmehdi Payabvash; John C Benson; Andrew E Tyan; Shayandokht Taleb; Alexander M McKinney
Journal:  J Stroke Cerebrovasc Dis       Date:  2017-11-29       Impact factor: 2.136

Review 8.  Glibenclamide in cerebral ischemia and stroke.

Authors:  J Marc Simard; Kevin N Sheth; W Taylor Kimberly; Barney J Stern; Gregory J del Zoppo; Sven Jacobson; Volodymyr Gerzanich
Journal:  Neurocrit Care       Date:  2014-04       Impact factor: 3.210

9.  Hospital acquired pneumonia is linked to right hemispheric peri-insular stroke.

Authors:  André Kemmling; Michael H Lev; Seyedmehdi Payabvash; Rebecca A Betensky; Jing Qian; Shihab Masrur; Lee H Schwamm
Journal:  PLoS One       Date:  2013-08-07       Impact factor: 3.240

10.  Permutation inference for the general linear model.

Authors:  Anderson M Winkler; Gerard R Ridgway; Matthew A Webster; Stephen M Smith; Thomas E Nichols
Journal:  Neuroimage       Date:  2014-02-11       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.